MCRB
Seres Therapeutics Inc
NASDAQ: MCRB · HEALTHCARE · BIOTECHNOLOGY
$7.05
-0.56% today
Updated 2026-04-29
Market cap
$67.91M
P/E ratio
11.02
P/S ratio
86.07x
EPS (TTM)
$0.64
Dividend yield
—
52W range
$7 – $30
Volume
0.1M
Seres Therapeutics Inc (MCRB) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-2.92M | $-5.32M | $-10.36M | $-40.84M | $43.92M | $-75.52M | $-62.85M | $-76.52M | $-93.61M | $6.69M | $-228.82M | $-117.35M | $-148.61M | $1.12M |
| Capital expenditures | $292000.00 | $174000.00 | $1.00M | $4.36M | $21.49M | $4.68M | $1.94M | $1.00M | $591000.00 | $9.57M | $9.82M | $7.97M | $380000.00 | $252000.00 |
| Depreciation | $25000.00 | $88000.00 | $190000.00 | $728000.00 | $4.21M | $7.26M | $7.86M | $7.60M | $6.58M | $5.95M | $6.63M | $6.24M | $5.47M | — |
| Stock-based comp | $28000.00 | $209000.00 | $2.07M | $9.69M | $16.86M | $17.36M | $16.64M | $8.34M | $8.82M | $20.22M | $25.48M | $34.10M | $20.97M | $10.84M |
| Free cash flow | $-3.22M | $-5.50M | $-11.36M | $-45.21M | $22.43M | $-80.20M | $-64.79M | $-77.52M | $-94.20M | $-2.88M | $-238.64M | $-125.33M | $-148.99M | $865000.00 |
| Investing cash flow | $-319000.00 | $-184000.00 | $-1.10M | $-137.13M | $-65.45M | $56.99M | $112.32M | $-30.52M | $-158.89M | $64.09M | $82.43M | $10.58M | $142.29M | — |
| Financing cash flow | $9.44M | $944000.00 | $123.99M | $137.72M | $2.14M | $83000.00 | $268000.00 | $86.23M | $303.42M | $1.18M | $129.60M | $71.70M | $-90.37M | — |
| Dividends paid | — | — | — | $262000.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-40.25M | $-19.39M | $-18.45M | $49.73M | $-20.81M | $50.92M | $71.95M | $-16.79M | — | — | — |